Skip to main content

OnabotulinumtoxinA for Chronic Migraine: Latest Evidence

 



This is the Medscape Neurology Minute. I am Dr. Alan Jacobs. Researchers from the Albert Einstein College of Medicine in Bronx, New York,[1] have published a study evaluating the effects of treatment with onabotulinumtoxinA on health-related quality of life and headache impact in adults with chronic migraine. The program consisted of a 24-week, double-blind phase, with two 12-week cycles followed by a 32-week open-label phase consisting of 3 cycles. Thirty-one injections of 5 units each, totaling 155 units, were administered to fixed sites. An additional 40 units could be administered as needed. They pooled results of 2 headache questionnaires assessing headache impact and migraine-specific quality of life. After random assignment, 688 patients received onabotulinumtoxinA and 696 received placebo. Mean scores at baseline on the headache-impact and quality-of-life questionnaires were comparable between the 2 groups, and 93% were severely affected based on impact scores ≥ 60. The investigators found that at 24 weeks, in comparison with placebo, onabotulinumtoxinA treatment significantly reduced headache impact scores and the proportion of patients with headache impact scores in the severe range at all timepoints, including week 24. Moreover, onabotulinumtoxinA treatments significantly improved all domains in the quality-of-life questionnaire at 24 weeks. The investigators concluded that treatment of chronic migraine with onabotulinumtoxinA is associated with significant and clinically meaningful reductions in headache impact and improvements in migraine-specific quality of life. This study was selected from Medscape Best Evidence. I'm Dr. Alan Jacobs.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more